I-MAB (IMAB) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. I-MAB's Free Cash Flow for the three months ended in Sep. 2024 was $0.00 Mil. I-MAB's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, I-MAB's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, I-MAB's current FCF Yield % is -271.24%.

The historical rank and industry rank for I-MAB's FCF Margin % or its related term are showing as below:

IMAB' s FCF Margin % Range Over the Past 10 Years
Min: -5673.45 Med: -1139.46 Max: 518.42
Current: -5673.45

During the past 7 years, the highest FCF Margin % of I-MAB was 518.42%. The lowest was -5673.45%. And the median was -1139.46%.

IMAB's FCF Margin % is ranked worse than
90% of 1030 companies
in the Biotechnology industry
Industry Median: -144.19 vs IMAB: -5673.45

I-MAB FCF Margin % Historical Data

The historical data trend for I-MAB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB FCF Margin % Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,933.86

27.59

-1,139.46

518.42

-4,761.33

I-MAB Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of I-MAB's FCF Margin %

For the Biotechnology subindustry, I-MAB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where I-MAB's FCF Margin % falls into.

I-MAB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

I-MAB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-185.692	/	3.9
	=	-4,761.33 %

I-MAB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	0	/	0
	=	%

I-MAB FCF Margin % Related Terms

Thank you for viewing the detailed overview of I-MAB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).